Design of peptide-based inhibitors of human islet amyloid polypeptide fibrillogenesis

Journal of Molecular Biology

Volumn 318, Issue 3, 2002, Pages 697-706

  Scrocchi, Louise A ^a   Chen, Yan ^a   Waschuk, Stefko ^a   Wang, Feng ^a   Cheung, Sindy ^a   Darabie, Audrey A ^a   McLaurin, JoAnne ^a,b   Fraser, Paul E ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Amyloid fibrils; Circular dichroism; Diabetes; Electron microscopy; Islet amyloid polypeptide

Indexed keywords

AMYLIN; ASPARAGINYLPHENYLALANYLGLYCYLALANYLISOLEUCYLLEUCINE; GLYCYLALANYLISOLEUCYLLEUCYLSERYLSERYLTHREONINE; PEPTIDE FRAGMENT; SERYLASPARAGINYLASPARAGINYLPHENYLALANYLGLYCYLALANINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BETA SHEET; CELL CULTURE; CELL LINE; CIRCULAR DICHROISM; CYTOTOXICITY; ELECTRON MICROSCOPY; FIBER; INCUBATION TIME; PRIORITY JOURNAL; PROTEIN CONFORMATION;

EID: 0036305837     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2836(02)00164-X     Document Type: Article

References (41)

1. On the relation of chronic interstitial pancreatitis to the islets of Langerhans and to diabetes mellitus
2. Islet amyloid polypeptide-like immunoreactivity in the islet β cells of type 2 (non-insulin-dependent) diabetic and non-diabetic individuals
3. Amyloid and polypeptide hormones: What is their relationship?
4. Localisation of islet amyloid peptide in lipofuscin bodies and secretory granules of human β-cells and in islets of type 2 diabetic subjects
5. Co-localisation of islet amyloid polypeptide and insulin in the β-cell secretory granules of the human pancreatic islets
6. Islet amyloid polypeptide (IAPP; amylin) influences the endocrine but not the exocrine rat pancreas
7. Inhibitory effect of rat amylin on the insulin responses to glucose and arginine in the perfused rat pancreas
8. Inhibitory action of islet amyloid polypeptide and calcitonin gene-related peptide on release of insulin from the isolated perfused rat pancreas
9. The pancreatic islet cell in insular amyloidosis in human diabetic and non-diabetic islets
10. Correlation of islet amyloid, reduced beta-cell mass with beta-cell function in diabetic monkeys
11. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus
12. Deficiency of total and nonglycosylated amylin in plasma characterizes subjects with impaired glucose tolerance and type 2 diabetes
13. Processing of synthetic pro-islet amyloid polypeptide (proIAPP) "amylin" by recombinant prohormone convertase enzymes, PC2 and PC3, in vitro
14. Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus
15. Effects of sequential proline substitutions on amyloid formation by human amylin 20-29
16. Amyloid fibrils formed from a segment of the pancreatic-islet amyloid protein
17. Islet amyloid polypeptide: Pinpointing amino acid residues linked to amyloid fibril formation
18. Analysis of amylin cleavage products provides new insights into the amyloidogenic region of human amylin
19. Identification of a novel human islet amyloid polypeptide β-sheet domain and factors influencing fibrillogenesis
20. Controlling amyloid β-peptide fibril formation with protease-stable ligands
21. The protofilament substructure of amyloid fibrils
22. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles
23. Different sensitivity to the cytotoxic action of IAPP fibrils in two insulin-producing cell lines, HIT-T15 and RIN5mF cells
24. β cell granule peptides affect human islet amyloid polypeptide (IAPP) fibril formation in vitro
25. Extensive islet amyloid formation is induced by development of Type II diabetes mellitus and contributes to its progression: Pathogenesis of diabetes in a mouse model
26. Conformational transitions of islet amyloid polypeptide (IAPP) in amyloid formation in vitro
27. The relation of islet amyloid to the clinical type of diabetes
28. Animal model of human disease: Spontaneous diabetes mellitus-islet amyoid complex in adult cats
29. Longitudinal studies on the development of diabetes in individual Macaca nigra
30. A feline model of experimentally induced islet amyloidosis
31. Amyloid fibril formation from full-length and fragments of amylin
32. Rotational resonance solid-state NMR elucidates a structural model of pancreatic amyloid
33. Identification of a penta- and hexapeptide of islet amyloid polypeptide (IAPP) and with amyloidogenic and cytotoxic properties
34. Distribution and kinetics of amylin in humans
35. Identification of a heparin binding domain in the N-terminal cleavage site of pro-islet amyloid polypeptide
36. Localisation of N-terminal pro-islet amyloid polypeptide in β-cells of man and transgenic mice
37. Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy
38. β-cell dysfunction and failure in type 2 diabetes
39. Changes in amylin and amylin-like peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM
40. Ultrastructural evidence that apoptosis is the mechanism by which human amylin evokes death in RINm5F pancreatic β cells
41. Preparation of synthetic human islet amyloid (IAPP) in a stable conformation to enable study of conversion to amyloid-like fibrils